Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
MNKDthis companyMannKind Corporation	$4.14	283.5×	-33.97×	4.97×	77.45×	-1108.3%	82.5%	11.1%	1.7%	-11.5%	5.8%	0.8%	-9.28×	14.48×	2.81×	1.7×	0.0%	1	-4.55	2	C+
AVLNAvalyn Pharma Inc. Common Stock	$29.41	-14.46×	-5.17×	0×	-12.96×	-95.6%	0.0%	0.0%	0.0%	35.7%	-67.5%	-6.6%	-0.01×	0.56×	0×	10.19×	0.0%	—	—	2	C
NRXPNRx Pharmaceuticals, Inc.	$2.42	-2.02×	-3.64×	47.35×	-1.83×	-67.8%	58.8%	-1324.4%	-2336.5%	179.6%	106.0%	-24.3%	-0.04×	0.26×	-24.18×	0.31×	0.0%	4	-13.9	2	C+
ORMPOramed Pharmaceuticals Inc.	$3.96	1.86×	0.59×	59×	0.97×	-70.9%	0.7%	-754.4%	3202.5%	32.1%	-6.0%	-9.4%	0×	-0.6×	0×	6.98×	0.0%	3	3.38	5	S-
SPRYARS Pharmaceuticals, Inc.	$2.89	-6.7×	10.05×	13.63×	-7.19×	-243.4%	75.8%	-212.9%	-203.3%	-149.9%	-62.2%	-14.9%	0.84×	-0.33×	-69.05×	7.28×	0.0%	2	-3.17	1	D+
XERSXeris Biopharma Holdings, Inc.	$15.40	2,242.86×	92×	4.32×	93.32×	-804.3%	81.7%	8.5%	0.2%	4.0%	8.9%	2.2%	2.76×	-5.77×	0.86×	2.19×	0.0%	5	1.35	2	C
Peer median	—	-2.02×	0.59×	13.63×	-1.83×	-95.6%	58.8%	-212.9%	0.0%	32.1%	-6.0%	-9.4%	0×	-0.33×	0×	6.98×	0.0%	4	-0.91	2	—